NEWS
Posters & Presentations
Navigator Medicines at the 2026 EADV Conference
Safety, PK, immunogenicity and biomarker modulation of NAV-240, an anti-OX40L/TNFα bispecific antibody, in randomized, double-blind, single and multiple ascending dose Phase 1 studies in healthy volunteers
>> VIEW POSTER
Preclinical characterization of NAV-242, a half-life extended bispecific antibody against TNFα and OX40L
>> VIEW POSTER
